Skip to content
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
Menu
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact

Publications & Presentations

Scientific publications and presentations reflect the quality of the innovative research being done by our scientists and clinical collaborators.

TriSalus Clinical Essentials™

Watch this highlight from our publications and presentations.

End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis

Tags: Retrospective Study, Drug Delivery, Embolization

  • READ PAPER

4:26 min

Share video

Browse Publications & Presentations

LIVER TUMORS
PANCREATIC TUMORS
OTHER
  • Mar 2023
  • Society for Immunotherapy of Cancer (SITC) 2023

Pressure-enabled intravascular delivery of SD-101 into the liver with systemic or subcutaneous checkpoint inhibitor for control of liver metastases in a murine model

Chandra C. Ghosh, Lauren Cournoyer, Jennie Liu, Alizee Ballarin, Jason LaPorte, Prajna Guha, Bryan F. Cox, Steven C. Katz
  • Feb 2023
  • Society of Interventional Oncology (SIO) 2023

Enhanced Delivery of a TLR9 Type C Agonist SD-101 to Liver Tumors in the Oncopig using Pressure Enabled Drug Delivery (PEDD) Versus a Standard Endhole Catheter

Thomas Hullinger, PhD, Dennis Griffin, MD, David Porter, MD, James Luethke, MD, Steven Katz, MD, Bryan Cox, PhD, David Jaroch, PhD
Tags: Pre-clinical Study, Pressure-Enabled Regional Immunotherapy, TLR9 Agonist
  • Jun 2022
  • Cancer Gene Therapy

Regional Infusion of a Class C TLR9 Agonist Enhances Liver Tumor Microenvironment Reprogramming and MDSC Reduction to Improve Responsiveness to Systemic Checkpoint Inhibition

Chandra C. Ghosh, Kara R. Heatherton, Kyle P. O’Connell, Ian S. Alexander, Deborah A. Greer, Jason LaPorte, Prajna Guha, Bryan F. Cox and Steven C. Katz
Tags: Pre-clinical Study, Pressure-Enabled Regional Immunotherapy, TLR9 Agonist
  • Apr 2022
  • Society for Immunotherapy of Cancer (SITC) 2022

Abstract No. 158628: PERIO-01: Enabling Tumor Microenvironment Reprogramming by a TLR9 Agonist Using Pressure-Enabled Drug Delivery™ (PEDD™) to Address Intrahepatic Immunosuppression and Drug Delivery Barriers

Sapna P. Patel, Steven C. Katz, Rahul A. Sheth, Ravi Murthy, Virginia Honaker, Chantell M. Farinas, Mara L. Casteneda, Laura Timciuc, Tarin Hennegan, Cara Haymaker, Victor G. Prieto, Bryan Cox, Ann-Marie Hulstine, Jason LaPorte, Ashley Moody, Marlana Orloff and Richard D. Carvajal
Tags: Clinical Trial, Pressure-Enabled Regional Immunotherapy, TLR9 Agonist
  • Nov 2021
  • Diagnostic and Interventional Radiology

Antireflux Catheter Improves Tumor Targeting in Liver Radioembolization with Resin Microspheres

Philippe d’Abadie, Stephan Walrand, Pierre Goffette, Nadia Amini, Aline van Maanen, Renaud Lhommel and François Jamar
Tags: Drug Delivery, Embolization, Retrospective Study
  • Apr 2021
  • Intrahepatic TLR9 Activation and Immunomodulation Compared to Systemic Infusion​

Abstract No. 1793: Regional Administration of Class C CpG Oligodeoxynucleotides Results in Superior Intrahepatic TLR9 Activation and Immunomodulation Compared to Systemic Infusion

Chandra C. Ghosh, Kara Heatherton, Kyle O’Connell, Jason LaPorte, Prajna Guha, Bryan F. Cox, David Jaroch and Steven C. Katz
Tags: Immunomodulation, Pre-clinical Trial, TLR9 Agonist
  • Aug 2020
  • Journal for Immunotherapy of Cancer

HITM-SURE: Hepatic Immunotherapy for Metastases Phase Ib Anti-CEA CAR-T Study Utilizing Pressure Enabled Drug Delivery

Steven C. Katz, Ashley E. Moody, Prajna Guha, John C. Hardaway, Ethan Prince, Jason LaPorte, Mirela Stancu, Jill E. Slansky, Kimberly R. Jordan, Richard D. Schulick, Robert Knight, Abdul Saied, Vincent Armenio and Richard P. Junghans
Tags: CAR-T, Case Report, Pressure-Enabled Regional Immunotherapy
  • Jun 2019
  • American Society of Clinical Oncology (ASCO) Annual Meeting

Abstract No. 9555: Phase 1b/2, Open Label, Multicenter Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced/Metastatic Melanoma Resistant to Anti-PD-1/PD-L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870)

A. Amin, G.V. Long, M. Milhem, C.J. Hoimes, T. Medina, R. M. Conry, C. Lao, G. Daniels, S. Reddy, R. H. I. Andtbacka, M. Barve, M. Shaheen, T. Tüting, M. Chisamore, E. Schmidt, B. Xing, C. Guiducci, C. Obiozor, T. Bagulho, E. Gamelin, R. Janssen and A. Ribas
Tags: Clinical Trial, Immunomodulation, TLR9 Agonist
  • Jan 2019
  • Oncogene

STAT3 Inhibition Induces Bax-dependent Apoptosis in Liver Tumor Myeloid-Derived Suppressor Cells

Prajna Guha, Jillian Gardell, Josephine Darpolor, Marissa Cunetta, Matthew Lima, George Miller, N. Joseph Espat, Richard P. Junghans and Steven C. Katz
Tags: Immunomodulation, Pre-clinical Study, TLR9 Agonist
  • Jan 2019
  • Cardiovascular and Interventional Radiology

End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis

Joseph J. Titano, Aaron M. Fischman, Arnav Cherian, Madeline Tully, Lance L. Stein, Louis Jacobs, Raymond A. Rubin, Michael Bosley, Steve Citron, Dean W. Joelson, Roshan Shrestha and Aravind Arepally
Tags: Drug Delivery, Embolization, Retrospective Study
  • Nov 2018
  • Society for Immunotherapy of Cancer (SITC) 2018

HITM-SURE: Phase Ib CAR-T Hepatic Artery Infusion Trial for Stage IV Adenocarcinoma using Pressure-Enabled Drug Delivery Technology

Steven C. Katz, Prajna Guha, John C. Hardaway, Ethan Prince, Ashley Moody, Jill E. Slansky, Kimberly R. Jordan, Richard D. Schulick, Robert Knight, Jerry Zeldis, Vincent Armenio, N. Joseph Espat and Richard P. Junghans
Tags: CAR-T, Clinical Trial, Drug Delivery
  • Apr 2018
  • Journal of Vascular and Interventional Radiology

Abstract No. 133: Surefire Infusion System (SIS) Hepatocellular Carcinoma Registry Study Interim Results: a Multicenter Study of the Safety, Feasibility, and Outcomes of the SIS Expandable-Tip Microcatheter in DEB-TACE

B. Kapoor, F. Contreras, M. Katz, A. Arepally, A. Fischman, S. Rose, A. Kim and J. Ferraro
Tags: Clinical Trial, Drug Delivery, Embolization
  • Sep 2017
  • PlOS One

Short-term Imaging Response after Drug-Eluting Embolic Trans-Arterial Chemoembolization Delivered with the Surefire Infusion System® for the Treatment of Hepatocellular Carcinoma

Alexander Y. Kim, Shelby Frantz, Pranay Krishnan, Danielle DeMulder, Theresa Caridi, George Emmett Lynskey and James B. Spies
Tags: Clinical Trial, Drug Delivery, Embolization
  • May 2015
  • Journal of Vascular and Interventional Radiology

The Impact of an Antireflux Catheter on Target Volume Particulate Distribution in Liver-Directed Embolotherapy: A Pilot Study

Alexander S. Pasciak, James H. McElmurray, Austin C. Bourgeois, R. Eric Heidel and Yong C. Bradley
Tags: Drug Delivery, Embolization, Prospective Study
Load More
  • Mar 2023
  • Society of Interventional Radiology (SIR) 2023

Pancreatic Retrograde Venous Infusion (PRVI) Significantly Enhances Delivery of NearIR Labelled SD-101 TLR9 Agonist to Targeted Regions of the Porcine Pancreas.

David B Jaroch, David J Porter, Dennis Griffin, Steven Katz, Bryan Cox
  • Jan 2023
  • ASCO-GI 2023

Pressure-Enabled Drug Delivery (PEDDTM) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model

Jayanth S Shankara Narayanan, Diego A Vicente, Benedict A Capacio, Yujia Liu, Jason P LaPorte, Bryan F Cox, David B Jaroch, Steven C Katz, Rebekah R White
Tags: Pre-clinical Study, Pressure-Enabled Regional Immunotherapy, TLR9 Agonist
Load More

There are currently no publications available.

  • Jun 2019
  • American Society of Clinical Oncology (ASCO) Annual Meeting

Abstract No. 9534: Phase 1b/2, Open Label, Multicenter, Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced Melanoma Who Are Naïve to Anti-PD-1/L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870)

M. Milhem, G.V. Long, C.J. Hoimes, A. Amin, C. Lao, R.M. Conry, J. Hunt, G. Daniels8 M. Almubarak, M. Shaheen, T. Medina, M. Barve, S. Bishnoi, E. Abdi, M. Chisamore, B. Xing, C. Guiducci, E. Gamelin, R. Janssen and A. Ribas
Tags: Clinical Trial, Immunomodulation, TLR9 Agonist
  • Jun 2019
  • American Society of Clinical Oncology (ASCO) Annual Meeting

Abstract 6039: Phase 1b/2, Open Label, Multicenter Study of Intratumoral SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001/KEYNOTE-184, NCT02521870)

E. Cohen, L. Nabell, A. Ribas, T. Day, G. Daniels, M. Milhem, S. Deva, M. Jameson, O. Guntinas-Lichius, M. Almubarak, M. Stroher, E. Whitman, M. Chisamore, C. Obiozor, T. Bagulho, C. Guiducci, E . Gamelin, R. Janssen and A. Algazi
Tags: Clinical Trial, Immunomodulation, TLR9 Agonist
  • Oct 2018
  • Cancer Discovery

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

Antoni Ribas, Theresa Medina, Shivaani Kummar, Asim Amin, Anusha Kalbasi, Joseph J. Drabick, Minal Barve, Gregory A. Daniels, Deborah J. Wong, Emmett V. Schmidt, Albert F. Candia, Robert L. Coffman, Abraham C.F. Leung and Robert S. Janssen
Tags: Clinical Trial, Immunomodulation, TLR9 Agonist
  • Oct 2018
  • Cancer Discovery

In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma

Matthew J. Frank, Patrick M. Reagan, Nancy L. Bartlett, Leo I. Gordon, Jonathan W. Friedberg, Debra K. Czerwinski, Steven R. Long, Richard T. Hoppe, Robert Janssen, Albert F. Candia, Robert L. Coffman and Ronald Levy
Tags: Clinical Trial, Immunomodulation, TLR9 Agonist
  • Oct 2016
  • PNAS

Intratumoral Injection of a CpG Oligonucleotide Reverts Resistance to PD-1 Blockade by Expanding Multifunctional CD8+ T Cells

Shu Wang, Jose Campos, Marilena Gallotta, Mei Gong, Chad Crain, Edwina Naik, Robert L. Coffman and Cristiana Guiducci
Tags: Immunomodulation, Pre-clinical Trial, TLR9 Agonist
Load More
© 2023 TriSalus Life Sciences, Inc. All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use
Linkedin Twitter
Linkedin Twitter
© 2023 TriSalus Life Sciences, Inc.
All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

YES
CANCEL